NCT05640791 is a Phase 2 clinical trial of Cisplatin in Resectable Biliary Tract Cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital.

Who is sponsoring NCT05640791?

NCT05640791 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT05640791?

Interventions in NCT05640791: Cisplatin, Gemcitabine, Nab-paclitaxel, Durvalumab.

What condition does NCT05640791 study?

NCT05640791 studies Resectable Biliary Tract Cancer.

Is NCT05640791 still recruiting?

NCT05640791 is currently status unknown. Last updated 7 December 2022.

Last reviewed 2022-12-07 · How we verify

NCT05640791

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Status unknown Phase 2 Last updated 7 December 2022

What this trial tests

Phase 2 trial testing Cisplatin in Resectable Biliary Tract Cancer in 40 participants. Status unknown.

Timeline

1 December 2022

Primary endpoint
31 December 2023

31 December 2024

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 December 2022
Primary completion	31 December 2023
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Cisplatin (cisplatin) — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →
Nab-paclitaxel (nab-paclitaxel) — full drug profile →
Durvalumab — full drug profile →

Conditions studied

Resectable Biliary Tract Cancer — all drugs for Resectable Biliary Tract Cancer →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

Adults 18 to 75, any sex, with Resectable Biliary Tract Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how well gemcitabine, cisplatin, nab-paclitaxel and durvalumab work before surgery in treating participants with Biliary Tract Cancer. The international multicenter phase III clinical study TOPAZ-1 has confirmed that durvalumab combined with gemcitabine and cisplatin can bring survival benefits to advanced BTC. Drugs used in chemotherapy, such as nab-paclitaxel, cisplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy and Durvalumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Design of studies on neoadjuvant therapy for intrahepatic cholangiocarcinoma.
Cheng Y, Li X. · · 2025 · cited 2× · PMID 39897772 · DOI 10.1016/j.heliyon.2024.e41356
Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next?
Ceniceros L, Torre M, Landa Magdalena A, Sangro P, et al · · 2025 · cited 1× · PMID 40940908 · DOI 10.3390/cancers17172811
Macrophage-rich niches regulate T cell dynamics at the liver invasive margin during gallbladder cancer progression
Li M, Liu Z, Shan S, Jia Z, et al ·

Verify or expand the search:

Other trials of Cisplatin

Trials testing the same drug.

NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07195734 — Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer · Phase 2 · recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05640791 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 7 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05640791.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing